Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics
IART Price/Volume Stats
| Current price | $45.04 | 52-week high | $59.33 |
| Prev. close | $44.75 | 52-week low | $33.44 |
| Day low | $44.16 | Volume | 692,400 |
| Day high | $45.40 | Avg. volume | 500,048 |
| 50-day MA | $42.44 | Dividend yield | N/A |
| 200-day MA | $41.53 | Market Cap | 3.52B |
IART Stock Price Chart Interactive Chart >
IART POWR Grades
- Value is the dimension where IART ranks best; there it ranks ahead of 79.47% of US stocks.
- The strongest trend for IART is in Growth, which has been heading up over the past 26 weeks.
- IART's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
IART Stock Summary
- With a price/earnings ratio of 31.63, INTEGRA LIFESCIENCES HOLDINGS CORP P/E ratio is greater than that of about 74.77% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for IART is currently 19.15, higher than 75.09% of US stocks with positive operating cash flow.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IART comes in at 9.87% -- higher than that of 83.22% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to INTEGRA LIFESCIENCES HOLDINGS CORP are ORGO, JOUT, CW, HUN, and ALOT.
- Visit IART's SEC page to see the company's official filings. To visit the company's web site, go to www.integralife.com.
IART Valuation Summary
- IART's price/sales ratio is 2.2; this is 0% higher than that of the median Healthcare stock.
- IART's price/earnings ratio has moved up 14.6 over the prior 243 months.
Below are key valuation metrics over time for IART.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IART | 2023-12-29 | 2.2 | 2.2 | 33.8 | 28.9 |
| IART | 2023-12-28 | 2.2 | 2.2 | 34.1 | 29.0 |
| IART | 2023-12-27 | 2.2 | 2.2 | 34.0 | 29.0 |
| IART | 2023-12-26 | 2.2 | 2.2 | 34.4 | 29.3 |
| IART | 2023-12-22 | 2.3 | 2.2 | 34.6 | 29.3 |
| IART | 2023-12-21 | 2.2 | 2.2 | 34.4 | 29.2 |
IART Growth Metrics
- Its 2 year price growth rate is now at 21.32%.
- The 5 year price growth rate now stands at 11.72%.
- Its year over year revenue growth rate is now at 13.17%.
The table below shows IART's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1,565.168 | 248.412 | 172.988 |
| 2022-06-30 | 1,566.838 | 262.878 | 166.302 |
| 2022-03-31 | 1,559.015 | 287.69 | 156.582 |
| 2021-12-31 | 1,542.448 | 312.427 | 169.075 |
| 2021-09-30 | 1,525.571 | 323.412 | 216.435 |
| 2021-06-30 | 1,508.942 | 310.272 | 205.543 |
IART's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IART has a Quality Grade of C, ranking ahead of 70.12% of graded US stocks.
- IART's asset turnover comes in at 0.411 -- ranking 114th of 186 Medical Equipment stocks.
- XENT, ALGN, and CODX are the stocks whose asset turnover ratios are most correlated with IART.
The table below shows IART's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.411 | 0.614 | 0.104 |
| 2021-06-30 | 0.416 | 0.616 | 0.103 |
| 2021-03-31 | 0.388 | 0.613 | 0.086 |
| 2020-12-31 | 0.395 | 0.620 | 0.065 |
| 2020-09-30 | 0.406 | 0.620 | 0.060 |
| 2020-06-30 | 0.411 | 0.617 | 0.030 |
IART Price Target
For more insight on analysts targets of IART, see our IART price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $77.70 | Average Broker Recommendation | 1.75 (Moderate Buy) |
Integra LifeSciences Holdings Corporation (IART) Company Bio
Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.
Latest IART News From Around the Web
Below are the latest news stories about INTEGRA LIFESCIENCES HOLDINGS CORP that investors may wish to consider to help them evaluate IART as an investment opportunity.
Integra (IART) to Advance ENT Division With New Buyout DealIntegra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition. |
Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.Provides a unique opportunity to build scale and capture a leadership position in the attractive ENT device segment with Acclarent’s established commercial scale, strong brand recognition, differentiated portfolio, and robust innovation pipeline. Generates shareholder value; transac |
Integra to buy J&J’s Acclarent for $275MIntegra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures. |
Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of DirectorsJeff Graves Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 202 |
Integra Gains From New Product Launches, Mounting Costs AilIntegra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America. |
IART Price Returns
| 1-mo | 6.25% |
| 3-mo | 16.50% |
| 6-mo | 5.98% |
| 1-year | -21.72% |
| 3-year | -33.98% |
| 5-year | -13.27% |
| YTD | 3.42% |
| 2023 | -22.33% |
| 2022 | -16.30% |
| 2021 | 3.19% |
| 2020 | 11.39% |
| 2019 | 29.22% |
Continue Researching IART
Want to do more research on Integra Lifesciences Holdings Corp's stock and its price? Try the links below:Integra Lifesciences Holdings Corp (IART) Stock Price | Nasdaq
Integra Lifesciences Holdings Corp (IART) Stock Quote, History and News - Yahoo Finance
Integra Lifesciences Holdings Corp (IART) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...